Edrecolomab (Panorex®, GSK) is a murine IgG2a monoclonal antibody derived from the original 17-1A murine mAb, and directed to the epithelial cell adhesion molecule EpCAM (EGP-2; CD326; 17-1A). Five anti-EpCAM monoclonal antibodies have been tested in cancer patients: murine edrecolomab, its chimeric IgG1 antibody version, the humanized and the fully human IgG1 antibodies (3622W94 and ING-1, respectively), and adecatumumab (MT201). None of them have shown to be effective as anti-neoplastic biomedicines. EpCAM is one of the first identified tumor-associated antigens expressed on human colon adenocarcinoma. However, EpCAM is also expressed by pancreatic, prostate, breast, kidney, lung, and ovarian tumors. It has also been selected as target of antitumoral vaccines.
KeywordsOvarian Tumor Effector Capacity Human Colon Adenocarcinoma IgG2 Molecule EpCAM Expression
- 2.Niedzwiecki D, Bertagnolli MM, Warren RS et al (2011) Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 29:3146–3152PubMedCrossRefGoogle Scholar
- 4.Gires O, Bauerle PA (2010) EpCAM as target in cancer therapy. J Clin Cancer 28:e239–240Google Scholar